Loading…
Immunocore Holdings plc is projected to rise to $36.06 by 2027, a +13% move from its current price of $31.95. IMCR is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $31.34 | $31.96 | $32.59 | +0.03% |
| Jul 15 | $31.10 | $31.97 | $32.86 | +0.06% |
| Jul 16 | $30.92 | $31.98 | $33.08 | +0.10% |
| Jul 17 | $30.77 | $31.99 | $33.26 | +0.13% |
| Jul 18 | $30.64 | $32.00 | $33.43 | +0.16% |
| Jul 19 | $30.52 | $32.01 | $33.58 | +0.19% |
| Jul 20 | $30.41 | $32.02 | $33.72 | +0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $30.41 | $32.02 | $33.72 | +0.23% |
| Week 2 | $29.84 | $32.10 | $34.52 | +0.45% |
| Week 3 | $29.42 | $32.17 | $35.17 | +0.68% |
| Week 4 | $29.08 | $32.24 | $35.74 | +0.91% |
| Week 5 | $28.79 | $32.31 | $36.26 | +1.14% |
| Week 6 | $28.54 | $32.39 | $36.75 | +1.37% |
| Week 7 | $28.32 | $32.46 | $37.21 | +1.60% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Immunocore Holdings plc is a healthcare company that develops and commercializes immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME.
In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Immunocore Holdings plc, IMCR, is a healthcare company with a current price of $33.40 and a market capitalization of $1.7B. It ranks 2180 by market cap. The stock’s price action sits within a broader forecast that envisions a rising average price over time, with later years showing stronger upside.
The 30-day technical picture currently flags bullish momentum, supported by near-term levels and a defined trading range.
A major floor 21.2% below — a decisive break under it would weaken the trend.
The nearest floor, 13.0% below — buyers have tended to step in here.
The nearest ceiling, 5.7% above — a clean break opens room to run.
A major ceiling 16.3% above — clearing it would confirm fresh momentum.
Key IMCR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IMCR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $32.83 | Sell | $32.56 | Sell |
| MA 10 | $32.14 | Sell | $32.05 | Sell |
| MA 20 | $30.60 | Buy | $31.13 | Buy |
| MA 50 | $29.56 | Buy | $30.33 | Buy |
| MA 100 | $30.42 | Buy | $30.71 | Buy |
| MA 200 | $32.51 | Sell | $31.69 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.28 | Neutral |
| Stoch RSI (14) | 24.31 | Neutral |
| CCI (20) | 57.97 | Neutral |
| Williams %R (14) | -39.96 | Info |
| MACD (12,26,9) | 0.25 | Buy |
| ROC (12) | 9.42 | Buy |
| Bollinger %B (20,2) | 0.69 | Neutral |
| Stochastic %K (14) | 60.04 | Neutral |
| TRIX (15) | 0.38 | Buy |
| Awesome (5,34) | 2.97 | Buy |
| Ultimate (7,14,28) | 57.49 | Neutral |
| Momentum (10) | 1.41 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 33.42 | Sell |
| ADX (14) | 20.81 | Buy |
| ATR (14) | 0.63 | Info |
The near-term technical picture is bullish, with RSI(14) at 70 indicating strong positive momentum. The moving averages show SMA50 at $29.32 and SMA200 at $32.52, with a defined support at $27.79 and resistance at $33.40. The 30-day trading range runs from $29.42 to $37.92, outlining a constructive short-term path.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $27.79 | $31.95 | $41.70 | 0% | Neutral | |
| $29.47 | $36.06 | $46.17 | +13% | Neutral | |
| $30.14 | $37.60 | $49.49 | +18% | Neutral | |
| $32.33 | $40.98 | $55.12 | +28% | Bullish | |
| $36.21 | $46.54 | $63.77 | +46% | Bullish | |
| $43.49 | $56.60 | $78.82 | +77% | Bullish | |
| $46.37 | $61.07 | $86.27 | +91% | Bullish | |
| $47.00 | $62.56 | $89.56 | +96% | Bullish | |
| $49.25 | $66.25 | $96.01 | +107% | Bullish | |
| $51.33 | $69.72 | $102.19 | +118% | Bullish | |
| $72.09 | $102.31 | $157.36 | +220% | Bullish | |
| $146.71 | $224.00 | $369.94 | +601% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $27.79 | $31.95 | $37.48 | +0.00% |
| August 2026 | $27.37 | $32.05 | $38.35 | +0.31% |
| September 2026 | $27.96 | $32.91 | $39.70 | +2.68% |
| October 2026 | $27.84 | $32.90 | $39.97 | -0.01% |
| November 2026 | $27.71 | $32.87 | $40.15 | -0.11% |
| December 2026 | $28.53 | $33.95 | $41.70 | +3.30% |
Click any year to see its month-by-month IMCR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, IMCR could reach as high as $41.70, with a base case around $31.95 and support toward $27.79 — roughly 0% from $31.95. Price action looks broadly range-bound.
Expect IMCR to range from $29.47 to $46.17 through 2027. The $36.06 average target implies a +13% move from current prices. That is up +13% on the projected 2026 average. A consolidation phase looks the most probable path here.
The IMCR price prediction for 2028 points to an average of $37.60 (low $30.14, high $49.49) — a potential gain of +18% on today's $31.95. Price action looks broadly range-bound.
In 2029, IMCR is projected to trade between $32.33 and $55.12, averaging $40.98 — a potential gain of +28% from today's $31.95. That is up +9% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Immunocore Holdings plc's 2030 outlook centres on $46.54, within a $36.21 to $63.77 range. That is up +14% on the projected 2029 average. That marks a +46% change versus current levels. Momentum favours further upside here.
By 2031, IMCR could reach as high as $78.82, with a base case around $56.60 and support toward $43.49 — roughly +77% from $31.95. Buyers look set to stay in control over this stretch.
Expect IMCR to range from $46.37 to $86.27 through 2032. The $61.07 average target implies a +91% move from current prices. That is up +8% on the projected 2031 average. Momentum favours further upside here.
The IMCR price prediction for 2033 points to an average of $62.56 (low $47.00, high $89.56) — a potential gain of +96% on today's $31.95. Buyers look set to stay in control over this stretch.
In 2034, IMCR is projected to trade between $49.25 and $96.01, averaging $66.25 — a potential gain of +107% from today's $31.95. That is up +6% on the projected 2033 average. Momentum favours further upside here.
Immunocore Holdings plc's 2035 outlook centres on $69.72, within a $51.33 to $102.19 range. That is up +5% on the projected 2034 average. That marks a +118% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, IMCR could reach as high as $157.36, with a base case around $102.31 and support toward $72.09 — roughly +220% from $31.95. Momentum favours further upside here.
Expect IMCR to range from $146.71 to $369.94 through 2050. The $224.00 average target implies a +601% move from current prices. That is up +119% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in IMCR today (≈ 31.298905 IMCR) could be worth
$7,010.87
+$6,010.87 (+601%) by 2050 · US Dollar
Based on the average projected IMCR price of $224 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IMCRwould be worth at today's price.
$1,000 invested in IMCR on Jul 10, 2025 (≈ 28.208744 IMCR) would be worth
$901.27
-$98.73 (-9.9%) today · 0.90× · US Dollar
Based on a IMCR entry price of $35.45 vs. today's $31.95.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $32.5 | $983.08 | -1.7% |
| 1 month ago | $27.9 | $1,145.16 | +14.5% |
| 3 months ago | $31.05 | $1,028.99 | +2.9% |
| 6 months ago | $32.64 | $978.86 | -2.1% |
| 1 year ago | $35.45 | $901.27 | -9.9% |
| All time (5.0y) ago | $34.91 | $915.21 | -8.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IMCR forecast.
Our base-case forecast reaches $64.00 around 2034.
Implied market cap at $64.00: $3.26B
The multi-year forecast shows a steadily higher price path, with 2026 avg $33.40, 2030 avg $51.64, 2040 avg $119.10, and 2050 avg $266.92. The implied upside increases over time, with ROI rising to 54.6% by 2030, 256.6% by 2040, and 699.2% by 2050. Sentiment shifts from NEUTRAL in 2026 and 2027 to BULLISH from 2028 onward.
The forecast also shows a path of higher max values, culminating at $439.21 in 2050.
Tap a question to reveal the answer.
The 2030 forecast shows min $40.23, avg $51.64, max $70.62 with ROI 54.6% and sentiment BULLISH.
The forecast begins NEUTRAL in 2026, turns BULLISH from 2028 onward, with the avg price rising to $51.64 by 2030 and $266.92 by 2050, and ROI increasing to 699.2% by 2050.
Yes. The forecast max for 2033 is $100.22.
Current price is $33.40 and market cap is $1.7B.
RSI(14) is 70 with a BULLISH sentiment. SMA50 is $29.32 and SMA200 is $32.52, with support at $27.79 and resistance at $33.40. The 30-day range is $29.42 to $37.92 and annualized volatility is 40%.
Immunocore Holdings plc Community Discussion
0Share your Immunocore Holdings plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.